Quick answers
- What is Almotriptan used for?
- The FDA-approved label (Almotriptan, Ajanta Pharma USA Inc., December 31, 2025) says: “Almotriptan tablets, USP are 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more Important limitations …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Almotriptan have a boxed warning?
- No. None of the 3 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Almotriptan?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Almotriptan been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Almotriptan?
- 3 companies list prescription products of Almotriptan in the FDA NDC Directory, including Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc. and Ajanta Pharma USA Inc..
What Almotriptan is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Almotriptan tablets, USP are 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more Important limitations …
— FDA label: Almotriptan, Ajanta Pharma USA Inc., effective December 31, 2025. Read the full label on DailyMed →
The FDA has 3 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 3 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated |
|---|---|
| Route | Oral |
| Prescription products | 6 in the FDA NDC Directory |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| almotriptan malate 12.5 mg tablet, film coated | Generic | $16.46 per tablet |
| almotriptan malate 6.25 mg tablet, film coated | Generic | $16.06 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Mylan Pharmaceuticals Inc.2 products
- Teva Pharmaceuticals USA, Inc.2 products
- Ajanta Pharma USA Inc.2 products
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (3)
- ANDA078027Teva Pharms USA · July 7, 2015
- ANDA205171Mylan · November 9, 2015
- ANDA205523Ajanta Pharma Ltd · March 3, 2016
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 284204, 284205 |
|---|---|
| SPL set ID of the quoted label | 6fa380c4-c885-4743-85bf-88819ae68645 |
| FDA labels (SPL) | 3 |
| FDA applications | 3 ANDA |
| Active ingredients (FDA) | ALMOTRIPTAN MALATE |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Almotriptan, Ajanta Pharma USA Inc., effective December 31, 2025; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →